NAD+ therapy benefits: what human trials demonstrated (and what they didn’t). - Reddit

The clinical-outcomes question most NAD+ articles dodge

If you read ten popular articles about NAD+ benefits, you will see the same handful of claims: more energy, better cognition, slower aging, improved recovery. You will rarely see those claims tied to a specific randomized controlled trial in humans. That is the gap this article exists to close.

The mechanism story is real. NAD+ levels fall with age in human tissue. Sirtuins, PARPs, and CD38 all consume NAD+. Mitochondrial output depends on NAD+ cycling. Animal models show that raising NAD+ can rescue age-related dysfunction in mice. None of that is in dispute.

The harder question: when researchers have given NAD+ precursors (or direct NAD+) to humans in controlled trials, measured clinical or near-clinical endpoints, and compared against placebo, what have they found? The answer is more nuanced than the marketing suggests, and reading the primary literature is the only way to get it right.

A short framing before the trial-by-trial section:

• Mechanism is not outcome. “Sirtuin activation extends lifespan in yeast” is a mechanism finding. “Twelve weeks of nicotinamide riboside (NR) improved walking distance in adults over 65” would be an outcome finding. Most NAD+ marketing blends the two.
• Pharmacokinetics is not biology. Raising blood NAD+ metabolites confirms a precursor was absorbed and metabolized. It does not, by itself, prove tissue NAD+ rose, or that rising tissue NAD+ produced any clinical change.
• Most published human NAD+ trials are small and short. The bulk of the data sits in 8 to 12 week trials with 20 to 140 participants. A handful of well-designed, larger, longer trials are underway. None have yet been completed at the scale that resolves the open questions.

Energy and fatigue: what controlled human trials measured

“More energy” is the single most common claim made for NAD+ therapy. It is also the area where the gap between mechanism enthusiasm and outcome data is widest. Three trials anchor what we currently know.

Martens 2018: NR pharmacokinetics and vascular function in older adults

Martens and colleagues, in Nature Communications (2018; 9:1286), reported a randomized, double-blind, placebo-controlled crossover trial of nicotinamide riboside (NR) at 1,000 mg per day for six weeks in 24 healthy middle-aged and older adults (ages 55 to 79). The headline result was straightforward: NR was well tolerated, and it raised whole blood NAD+ by roughly 60%. That is a clean pharmacokinetic finding.

What it did not show was a robust energy or fatigue benefit. The trial was not powered to find one. It measured biomarkers (NAD+ metabolome, blood pressure, arterial stiffness) rather than patient-reported energy. Subgroup analysis suggested a possible reduction in systolic blood pressure and aortic stiffness in participants with elevated baseline values, which is a real signal worth replicating, but it is not a fatigue endpoint and the subgroup sizes were small.

What this trial supports: oral NR reliably raises blood NAD+ in older adults and is well tolerated at 1,000 mg per day for six weeks. Vascular signals warrant further study.

What it does not support: a quantified energy or fatigue benefit in healthy older adults.

Dollerup 2018: NR in obese, insulin-resistant men

Dollerup and colleagues, in the American Journal of Clinical Nutrition (2018; 108(2):343–353), reported a 12-week randomized, placebo-controlled trial of NR at 1,000 mg twice daily in 40 obese, insulin-resistant men. The endpoints were clinically meaningful: insulin sensitivity (gold-standard hyperinsulinemic-euglycemic clamp), body composition, and lipid mobilization.

The result, honestly, was largely null. NR raised NAD+ metabolites in blood but did not improve insulin sensitivity, beta-cell function, hepatic fat, or body composition compared to placebo. Lipid markers were largely unchanged.

This is one of the most carefully designed NAD+ precursor trials ever conducted, and it did not find the metabolic benefits the mechanism story predicted. That matters. A truthful read of the field has to weight Dollerup heavily.

What this trial supports: NR is well tolerated at 2,000 mg per day for 12 weeks in obese men.

What it does not support: a meaningful insulin-sensitivity or body-composition benefit from NR alone, at this dose, in this population, over this duration.

Conze 2019: long-term NR safety and metabolism

Conze, Brenner, and Kruger, in Scientific Reports (2019; 9:9772), reported an eight-week randomized, double-blind, placebo-controlled trial of NR (NIAGEN) at 100, 300, or 1,000 mg per day in 140 healthy overweight adults. This is the largest published RCT of an NAD+ precursor to date, and its primary aim was safety and dose-response pharmacokinetics rather than a clinical efficacy endpoint.

The findings were what you would hope for in a Phase II-style safety study: NR was well tolerated at all three doses, raised whole blood NAD+ in a dose-dependent fashion, and produced no serious adverse events. Mild adverse effects (nausea, fatigue, occasional muscle soreness) occurred at rates comparable to placebo.

Conze 2019 is important precisely because it does not over-claim. It establishes that the molecule is safe, that pharmacokinetics behave predictably, and that bigger efficacy trials can proceed on solid footing. It does not, by design, demonstrate clinical benefit.

The honest read on energy

Across the controlled human trial record, NAD+ precursors have not produced large, replicated improvements in measured energy expenditure, fatigue scales, or physical performance in healthy adults. They have produced reliable increases in blood NAD+ metabolites and an acceptable safety profile. Anyone telling you the literature shows a clean “NAD+ supplementation reduces fatigue” result is not reading the same papers.

That is not the same as saying NAD+ therapy does nothing for energy. It means the published controlled-trial evidence has not isolated a specific, quantified energy benefit attributable to NAD+ alone. Patient reports under clinician-supervised protocols are a different (and softer) category of evidence.

Cognitive function: where mechanism is strong but outcomes are scarce

NAD+ and cognition is a textbook example of mechanism-outcome gap. Neurons are highly metabolically active. Mitochondrial dysfunction is tightly linked to age-related cognitive decline. NAD+-dependent pathways regulate neuroinflammation, protein homeostasis, and DNA repair. The mechanistic case for studying NAD+ in cognition is excellent. The clinical-outcome data in healthy adults is, in 2026, quite thin.

A few honest reference points for the current literature:

• No large, completed RCT has shown NAD+ precursor supplementation improves validated cognitive testing scores (such as the Montreal Cognitive Assessment, the Repeatable Battery for the Assessment of Neuropsychological Status, or computerized executive function batteries) in healthy middle-aged or older adults.
• Parkinson’s disease is one neurological area where preliminary human work is more developed. Brakedal and colleagues (the NR-SAFE trial; the larger N-DOSE program) are pursuing NR in Parkinson’s, with early data suggesting NR raises cerebral NAD+ in patients and is well tolerated. Whether that translates to clinically meaningful symptom or progression effects is the question larger trials are designed to answer.
• Alzheimer’s and ataxia trials of NAD+ precursors exist at small to moderate scale, with mixed results. Most are exploratory and underpowered for definitive clinical conclusions.
• Healthy adult cognition remains the area where the literature is weakest. The intuitive “NAD+ for mental clarity” pitch is exactly the population where rigorous outcome data is hardest to find.

The translation gap here is not a hidden conspiracy. It reflects how hard it is to demonstrate cognitive benefit in healthy people: effect sizes are typically small, ceiling effects on testing are real, placebo response is high, and trial durations long enough to matter are expensive. Meaningful outcome data on NAD+ and cognition in healthy adults will likely take another five to ten years to mature.

Practical implication: a clinician recommending NAD+ for cognitive support today is leaning on mechanism, not outcome data. That is not necessarily wrong, but it should be named honestly.

Cardiometabolic findings: the most defensible benefits area

If there is a single area where the human outcome data lines up with the mechanism story most cleanly, it is cardiometabolic markers in middle-aged and older adults. The signals are not large, and they are not consistent across every trial, but the area is where evidence is least disappointing relative to the mechanistic prediction.

Vascular function and arterial stiffness

The Martens 2018 trial described above is the most cited single finding here. In the subgroup with elevated baseline systolic blood pressure or aortic pulse-wave velocity, NR appeared to reduce both modestly. The effect size was clinically interesting (in the range of a few mmHg of systolic reduction), and the mechanism, NAD+-dependent support of endothelial function and SIRT1-mediated nitric oxide signaling, is biologically plausible.

Replication in a larger trial is the key question. The signal is the kind that benefits enormously from a properly powered Phase III, because subgroup findings in small RCTs are well known to inflate.

Insulin sensitivity: the Yoshino versus Dollerup contrast

Yoshino and colleagues, in Science (2021), reported that 10 weeks of NMN at 250 mg per day improved muscle insulin sensitivity in prediabetic postmenopausal women. The effect was real and statistically significant, though it sat alongside the surprising observation that muscle NAD+ content did not measurably change with supplementation.

Dollerup 2018, on the other hand, found no insulin-sensitivity benefit of NR in obese, insulin-resistant men, despite a longer trial duration and a higher dose.

The discrepancy could reflect any of several real differences: the precursor used (NMN vs NR), the population (postmenopausal women vs middle-aged men), the dose, or the assay. The point is that the insulin-sensitivity story is mixed, not uniformly positive. The Yoshino finding is genuinely interesting and warrants replication. Dollerup is a sober counterpoint.

Lipids and inflammatory markers

Across the published trials, NAD+ precursor effects on LDL cholesterol, triglycerides, and inflammatory markers (CRP, IL-6) have been small and inconsistent. Some trials have reported modest reductions in CRP or specific cytokines; others have reported nothing. Nothing in the published record supports NAD+ therapy as a primary lipid or inflammation intervention.

Why this category is the most defensible

Cardiometabolic markers earn the “most defensible” label because three things line up: the mechanism is well-characterized (SIRT1, eNOS, mitochondrial efficiency), the trial endpoints are objective (blood pressure, pulse-wave velocity, insulin sensitivity), and the population in which signals appear (middle-aged and older adults with mildly elevated baseline values) matches the population where age-related NAD+ decline is real.

Setting expectations: even here, effect sizes are modest. The literature does not support NAD+ as a substitute for blood-pressure medications, statins, or metformin in patients with established disease. It supports NAD+ as a candidate for adjunctive support of vascular and metabolic health in middle-aged adults, pending larger replication.

Athletic performance and recovery: hype versus evidence

If a podcast convinced you NAD+ is a performance-enhancing intervention for athletes, the published trial record does not back that up.

A few representative data points:

• Dolopikou and colleagues (2020) reported that NR raised NAD+ metabolites in young and older recreationally active adults but did not improve maximal exercise performance or VO2max in either group.
• Stocks and colleagues (2021) found that NR did not enhance training adaptations in young men doing endurance training, despite raising blood NAD+ metabolites.
• Older-adult mobility (gait speed, six-minute walk distance, stair climb) is the area where the rationale is strongest and where ongoing trials are positioned. The data is preliminary.

Three honest takeaways for athletes considering NAD+ therapy:

1. In young, healthy, well-trained adults, the published outcome data does not support NAD+ as a performance enhancer. The mechanism prediction (raise NAD+, lift mitochondrial output, improve performance) does not appear in the trial record at this population.
2. In older adults with declining mobility, the signal is more plausible but the data is early. Larger trials in the next several years should clarify whether NAD+ repletion meaningfully improves functional capacity in aging populations.
3. In recovery specifically (post-exercise soreness, training tolerance), the published controlled trials are sparse. Patient reports exist; rigorous data does not.

The takeaway is not that NAD+ does nothing for athletes. It is that the high-volume claim space (“boost performance, accelerate recovery”) outruns the published evidence by a wide margin, and anyone selling NAD+ to a 28-year-old triathlete on those grounds is selling marketing, not data.

The “biological age” question

Epigenetic age clocks are one of the more fraught endpoints in the NAD+ literature. The promise is intuitive: if NAD+ repletion slows or reverses biological aging, a clock that estimates biological age should reflect it. The reality is more complicated.

What an epigenetic clock is

Epigenetic clocks estimate biological age from DNA methylation patterns at a defined set of CpG sites. The Horvath clock, introduced in Genome Biology (2013), trained on multi-tissue methylation data and produces an estimate that correlates strongly with chronological age across most tissue types. The Hannum clock (2013) is blood-specific. Later second-generation clocks, such as PhenoAge (Levine 2018) and GrimAge (Lu 2019), correlate more strongly with mortality, age-related disease incidence, and other functional outcomes than first-generation clocks.

What NAD+ trials have measured against clocks

A small number of NAD+ precursor trials have included epigenetic clock endpoints, mostly as exploratory secondary outcomes. The general picture: short-duration trials (8 to 12 weeks) at standard NR or NMN doses have not produced consistent, large reductions in biological age estimates compared to placebo. A handful of multi-component interventions that include NAD+ precursors (alongside other ingredients) have reported clock-age reductions, but isolating the NAD+ contribution from the rest of the protocol is generally not possible in those designs.

Methodological caveats with biological age as endpoint

• Tissue specificity: most trials use blood-derived methylation, which reflects hematopoietic cell composition more than systemic biological age. Shifts in immune-cell ratios can move clock readouts without changing aging in the tissues that matter (brain, muscle, vasculature).
• Within-person variability: individual epigenetic age estimates have meaningful test-retest variability. A “1.5 year reduction” in clock age over 12 weeks may sit inside the noise floor of the assay.
• Causal interpretation is hard: reducing a clock estimate is not the same as slowing the underlying aging biology. Clocks are correlational tools, not direct measures of mortality risk in an individual.
• Generation matters: effects on first-generation clocks (Horvath, Hannum) and second-generation clocks (GrimAge, PhenoAge, DunedinPACE) can diverge. A trial that improves one but not another is not the same as a trial that consistently slows aging.

The honest position: biological age is a useful research endpoint, not a clinical biomarker for treatment decisions. Anyone framing NAD+ therapy as proven to “reverse biological age” on the basis of small-n clock trials is overstating what the methodology supports.

The pharmacokinetic ceiling: why delivery method changes the outcomes question

Most published human NAD+ outcome trials use oral precursors (NR or NMN) because that is what regulatory pathways and supplement-grade bioavailability studies have allowed. Oral precursors raise blood NAD+ metabolites reliably. Whether they raise tissue NAD+ enough to produce the effects predicted by mechanism work is the rate-limiting question for the field.

Two specific PK realities matter when reading the outcomes literature:

• Tissue uptake is the bottleneck. Oral NR and NMN are absorbed and metabolized rapidly. Most of the rise in blood NAD+ metabolites reflects intermediates (nicotinamide, NMN, methyl-nicotinamide) rather than direct delivery of NAD+ into the cells where it works. Studies that have measured intracellular NAD+ in muscle (Yoshino 2021) or brain (in animal models) show that tissue-level repletion is partial, slow, and variable across tissues.
• Subcutaneous and IV NAD+ have different PK profiles. Direct administration bypasses first-pass metabolism and produces a different kinetic curve in blood. The key open question is whether that translates to higher or more durable intracellular NAD+ in target tissues. Outcome trials directly comparing oral precursors to subcutaneous or IV NAD+ in the same population are still rare.

For someone reading the outcomes literature, the PK ceiling has two practical implications.

First, a null result in an oral NR trial does not necessarily mean “NAD+ doesn’t work for this endpoint.” It may mean “1,000 mg of oral NR for 12 weeks did not raise tissue NAD+ enough to produce the predicted effect at this endpoint.” Those are different statements, and the field has not always distinguished them carefully.

Second, when patient reports under direct NAD+ protocols (subcutaneous or IV) describe effects that the published precursor trials have not demonstrated, the discrepancy is not automatically marketing. It can reflect a real PK difference. It can also reflect placebo, expectancy, or unmeasured co-interventions. Distinguishing those requires controlled trials using direct NAD+ in the same populations and endpoints, which the field is, in 2026, only starting to run at meaningful scale.

For the side-by-side route comparison in clinical practice, see NAD+ injections. The note here is narrower: when the outcomes literature is silent or negative, knowing which delivery route produced that data is part of reading it correctly.

Where to set expectations

If you are considering NAD+ therapy, the published outcomes literature supports a specific set of expectations. The expectations are real, but they are narrower than the marketing.

Strongest signals. Cardiometabolic markers in middle-aged and older adults: vascular function, blood pressure in mildly hypertensive subgroups, possibly muscle insulin sensitivity in selected populations. These are the endpoints where mechanism, plausible effect size, and observed signals converge.

Plausible signals, awaiting larger trials.Mobility and functional capacity in older adults. Adjunctive support for early Parkinson’s. Subjective recovery and sleep quality in supervised protocols (lower-quality evidence, but consistent enough to be worth tracking).

Weak signals. Cognitive enhancement in healthy adults. Performance enhancement in young trained athletes. Large measurable reductions in epigenetic age over short trial durations. Lipid and inflammatory marker improvements as primary outcomes.

A reasonable framing for someone considering NAD+ therapy is: the mechanism justifies clinical interest, particularly for adults over 45 with cardiometabolic risk markers. The outcomes data is real but modest, and it does not yet support the more aggressive longevity claims that dominate consumer marketing. A clinician-supervised protocol that names this honestly and tracks objective markers (blood pressure, fasting glucose, lipid panel, sleep quality, energy) over 8 to 12 weeks gives you the best chance of distinguishing real response from placebo in your own case.

Compounded NAD+ formulations are not FDA-approved drugs. Through PepScribe, they are prepared in the USA by licensed 503A pharmacies under clinician prescription, not 503B, not international. No hidden overseas supply chain. The standard is safety-first because the mechanism is interesting and the outcomes data is still maturing, exactly the situation where supervision matters most.